Written by Patricia Weiss
Frankfurt (Reuters) -CEO of Bayer faces increased investor pressure to achieve transformation efforts and reflect the expected decrease in profits this year, as the group is preparing to issue quarterly results on Wednesday.
CEO Bill Anderson in the middle of reducing administrative jobs, which speeds up decisions and reducing the red tape, and has developed plans to dismantle Bayer's various business.
But investors are wondering whether he is doing enough amid a large number of problems that have made less shares.
With the leadership in mid -2013, Anderson inherited the US claims charged with the disputed allegations that Gorposet caused by Bayer in cancer. Later that year, the thinnest blood that was based once in an experiment, leaving a huge gap in the drug development collection in Bayer.
Late last year, the medicine maker and pesticides said that the weakness in the global agricultural markets, which is the lifeline in the crop science unit in Bayer, means that the decrease in profits is likely to extend to 2025.
“We want to see successes that will already support the share price,” said Inka, head of the Sustainability and Corporate Governance Department at Deka.
He added: “By the end of the year, Anderson will be the CEO for nearly three years. If the CEO is not able to make an impact on the course of this time period, he will not be correct for this position.”
Another shareholder Bayer said that Anderson had taken steps in the right direction, but the stock market was waiting for more.
Manz said the results of the next fourth quarter “can be said that one of the last few opportunities for Bill Anderson to change the path.”
Modern market trends may provide some comfort, as Corteva, US Chemistry, last month spread a smaller loss in the fourth quarter with the help of strong sales sizes, and Basf in Germany, which also competes with Bayer in agricultural products, and the gain of size during the fourth quarter.
But more specifically with Bayer, investors will search for evidence of our delay in the United States' approval of a new generation of soy seeds to go with Weedkiller Dicamba will prepare for profits.
Annual analysts expect the average operating income to slide 2025 to 9.44 billion euros (9.96 billion dollars), a decrease from 10.0 billion in 2024. In the fourth quarter of last year, they expect a decrease of 25 % to 2.27 billion.
Bayer Bayer's purchase of $ 63 billion for American seeds and pesticides Monsanto under Anderson's predecessor in 2018 was a long -term bet on the strong growth in the agricultural supplies that made a mistake.
The post Bayer faces investors’ impatience ahead of fourth-quarter results first appeared on Investorempires.com.